Industry News

FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR+ Breast Cancer

Author(s):

Jinwei Zhang*   Pages 1 - 3 ( 3 )

Abstract:

Keywords:

Affiliation:

Read Full-Text article